CL2019003325A1 - Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. - Google Patents
Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca.Info
- Publication number
- CL2019003325A1 CL2019003325A1 CL2019003325A CL2019003325A CL2019003325A1 CL 2019003325 A1 CL2019003325 A1 CL 2019003325A1 CL 2019003325 A CL2019003325 A CL 2019003325A CL 2019003325 A CL2019003325 A CL 2019003325A CL 2019003325 A1 CL2019003325 A1 CL 2019003325A1
- Authority
- CL
- Chile
- Prior art keywords
- receptor
- heart failure
- fpr2
- lipoxin
- alx
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 101150103751 FPR2 gene Proteins 0.000 title 1
- 108010076288 Formyl peptide receptors Proteins 0.000 title 1
- 102000011652 Formyl peptide receptors Human genes 0.000 title 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 title 1
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 title 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 title 1
- 101100446655 Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) FKBP2 gene Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509489P | 2017-05-22 | 2017-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003325A1 true CL2019003325A1 (es) | 2020-04-17 |
Family
ID=62567841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003325A CL2019003325A1 (es) | 2017-05-22 | 2019-11-20 | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200069644A1 (enExample) |
| EP (1) | EP3630097A1 (enExample) |
| JP (1) | JP2020520948A (enExample) |
| KR (1) | KR20200006595A (enExample) |
| CN (1) | CN110662538A (enExample) |
| AU (1) | AU2018273382A1 (enExample) |
| BR (1) | BR112019024185A2 (enExample) |
| CA (1) | CA3064291A1 (enExample) |
| CL (1) | CL2019003325A1 (enExample) |
| CO (1) | CO2019013015A2 (enExample) |
| EA (1) | EA201992704A1 (enExample) |
| IL (1) | IL270749A (enExample) |
| MX (1) | MX2019013926A (enExample) |
| PE (1) | PE20200402A1 (enExample) |
| WO (1) | WO2018217684A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2869129T3 (es) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| CN119055775A (zh) * | 2022-07-30 | 2024-12-03 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
| CN118831080B (zh) * | 2024-09-24 | 2024-11-22 | 上海交通大学医学院附属仁济医院 | 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492552A2 (en) * | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| KR101645015B1 (ko) * | 2014-03-11 | 2016-08-03 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
-
2018
- 2018-05-22 MX MX2019013926A patent/MX2019013926A/es unknown
- 2018-05-22 EP EP18730584.2A patent/EP3630097A1/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033783 patent/WO2018217684A1/en not_active Ceased
- 2018-05-22 AU AU2018273382A patent/AU2018273382A1/en not_active Abandoned
- 2018-05-22 JP JP2019564446A patent/JP2020520948A/ja active Pending
- 2018-05-22 CN CN201880033663.XA patent/CN110662538A/zh active Pending
- 2018-05-22 PE PE2019002437A patent/PE20200402A1/es unknown
- 2018-05-22 US US16/612,438 patent/US20200069644A1/en not_active Abandoned
- 2018-05-22 BR BR112019024185-0A patent/BR112019024185A2/pt not_active Application Discontinuation
- 2018-05-22 CA CA3064291A patent/CA3064291A1/en active Pending
- 2018-05-22 KR KR1020197037388A patent/KR20200006595A/ko not_active Withdrawn
- 2018-05-22 EA EA201992704A patent/EA201992704A1/ru unknown
-
2019
- 2019-11-18 IL IL270749A patent/IL270749A/en unknown
- 2019-11-20 CL CL2019003325A patent/CL2019003325A1/es unknown
- 2019-11-21 CO CONC2019/0013015A patent/CO2019013015A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018217684A1 (en) | 2018-11-29 |
| AU2018273382A1 (en) | 2020-01-16 |
| US20200069644A1 (en) | 2020-03-05 |
| PE20200402A1 (es) | 2020-02-26 |
| CN110662538A (zh) | 2020-01-07 |
| IL270749A (en) | 2020-01-30 |
| CO2019013015A2 (es) | 2020-01-17 |
| CA3064291A1 (en) | 2018-11-29 |
| EP3630097A1 (en) | 2020-04-08 |
| EA201992704A1 (ru) | 2020-03-19 |
| BR112019024185A2 (pt) | 2020-06-02 |
| MX2019013926A (es) | 2020-01-20 |
| KR20200006595A (ko) | 2020-01-20 |
| JP2020520948A (ja) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013015A2 (es) | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca | |
| CL2020002224A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil péptido | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2019001963A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del péptido inhibidor gástrico (gipr). | |
| UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| UY37590A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| DOP2021000130A (es) | Moduladores de la expresion de hsd17b13 | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2016012368A (es) | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). | |
| MX2017006224A (es) | Derivados heterociclicos y usos de los mismos. | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| MX2018006635A (es) | Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona. | |
| MX373268B (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| MX378160B (es) | Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes. | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| NZ739139A (en) | Dopamine d3 receptor antagonists having a bicyclo moiety | |
| ECSP21088669A (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
| CL2015003286A1 (es) | (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos | |
| CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| EA201591795A1 (ru) | Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120 | |
| WO2019054891A3 (en) | Trpv2 antagonists |